You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PI3KD

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cushing Disease Trial (Fimepinostat)

Not yet recruiting
  • Cushing Disease
  • (no location specified)
Jul 31, 2023

Improving Prostate Lesion Classification and Development

Completed
  • Prostate Cancer
    • Nuernberg, Germany
      Department of Radiology and Nuclear Medicine, Klinikum Nuernberg
    Nov 2, 2023

    Endometrial Cancer, Ovarian Cancer Trial in Houston (Copanlisib, fulvestrant)

    Recruiting
    • Endometrial Cancer
    • Ovarian Cancer
    • Houston, Texas
      M D Anderson Cancer Center
    Sep 27, 2022

    Bioavailability Trial in Ruddington Nottingham (Belumosudil Tablet, Belumosudil Capsule)

    Completed
    Has Results
    • Bioavailability
    • Belumosudil Tablet
    • Belumosudil Capsule
    • Ruddington Nottingham, United Kingdom
      Quotient Clinical Limited
    May 9, 2022

    Alzheimer Trial in Hialeah, Maitland, Winter Park ([18F]PI-2620)

    Recruiting
    • Alzheimer Disease
    • Hialeah, Florida
    • +2 more
    Jan 18, 2023

    Urinary Tract Infection, Acute Pyelonephritis Trial (TBP-PI-HBr, Imipenem-cilastatin, Dummy Infusion)

    Not yet recruiting
    • Urinary Tract Infection
    • Acute Pyelonephritis
    • (no location specified)
    Sep 22, 2023

    Advanced Cancers, Solid Tumors Trial in Houston (Pazopanib, Everolimus)

    Active, not recruiting
    • Advanced Cancers
    • Solid Tumors
    • Houston, Texas
      University of Texas MD Anderson Cancer Center
    Dec 16, 2022

    Relapsed/Refractory Large Granular T Lymphocytic Leukemia Trial in Zhoukou, Tianjin (Linperlisib)

    Not yet recruiting
    • Relapsed/Refractory Large Granular T Lymphocytic Leukemia
    • Zhoukou, Henan, China
    • +1 more
    Dec 22, 2022

    Hyperglycemia Drug Induced Trial in Durham (REMD-477)

    Terminated
    • Hyperglycemia Drug Induced
    • REMD-477
    • Durham, North Carolina
      Duke University Medical Center
    Nov 4, 2022

    Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer Trial in Miami (AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor +

    Not yet recruiting
    • Breast Cancer
    • +3 more
    • Miami, Florida
      University of Miami
    Apr 12, 2023

    Autoimmune Hemolytic Anemia, Failure of Two Rounds of Treatment Trial in Zhoukou, Tianjin (Linperlisib)

    Not yet recruiting
    • Autoimmune Hemolytic Anemia
    • Failure of Two Rounds of Treatment
    • Zhoukou, Henan, China
    • +1 more
    Jan 7, 2023

    Advanced Solid Tumor Trial in Sutton, Manchester (SL-901)

    Recruiting
    • Advanced Solid Tumor
    • Sutton, Surrey, United Kingdom
    • +1 more
    May 16, 2022

    NSCLC Trial in New Haven, Farmington (KD019, Erlotinib)

    Terminated
    • Carcinoma, Non-Small-Cell Lung
    • New Haven, Connecticut
    • +1 more
    May 9, 2022

    PIK3CA Mutation-Related Tumors Trial in Shanghai (WX390)

    Completed
    • PIK3CA Mutation-Related Tumors
    • Shanghai, Shanghai, China
      Shanghai East Hospital
    Nov 9, 2023

    Metastatic Breast Cancer Trial in East Melbourne (BYl719)

    Completed
    • Metastatic Breast Cancer
    • East Melbourne, Victoria, Australia
      Peter MacCallum Cancer Centre
    Aug 11, 2022

    Bile Acids in Acute Insulin Resistance

    Recruiting
    • PI3K Gene Mutation
    • +4 more
    • Drug-induced acute insulin resistance due to PI3K inhibitor, AKT inhibitor, or mTOR inhibitor
    • New York, New York
      Columbia University Medical Center
    Oct 6, 2022

    Novel Genetic Disorders of the Immune System

    Recruiting
    • PI3KCD
    • +3 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Feb 2, 2023

      Estrogen Receptor-positive Breast Cancer Trial in Nashville (2-Week Ketogenic Diet, Letrozole)

      Recruiting
      • Estrogen Receptor-positive Breast Cancer
      • Nashville, Tennessee
        Vanderbilt-Ingram Cancer Center
      Sep 20, 2022

      End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection Trial in Los Angeles (Donor CD34+,

      Not yet recruiting
      • End Stage Kidney Disease
      • +3 more
      • Donor CD34+, CD3+. and belumosudil
      • Los Angeles, California
        University of California, Los Angeles
      Apr 6, 2023

      Multiple Myeloma Trial (Elranatamab, Elotuzumab, Pomalidomide)

      Not yet recruiting
      • Multiple Myeloma
      • (no location specified)
      Nov 28, 2023

      Leukemia, Acute Lymphocytic Trial in Durham (Copanlisib)

      Recruiting
      • Leukemia, Acute Lymphocytic
      • Durham, North Carolina
        Duke Cancer Center
      Jun 28, 2022

      Metastatic Breast Cancer, Advanced Breast Cancer, HR-positive Breast Cancer Trial (OP-1250, Ribociclib, Alpelisib)

      Not yet recruiting
      • Metastatic Breast Cancer
      • +3 more
      • (no location specified)
      Aug 18, 2022

      Melanoma and Other Malignant Tumors of Skin, Metastatic Melanoma Trial in Houston (GSK2636771, Pembrolizumab)

      Active, not recruiting
      • Melanoma and Other Malignant Neoplasms of Skin
      • Metastatic Melanoma
      • Houston, Texas
        University of Texas MD Anderson Cancer Center
      Sep 22, 2022

      Lung Cancer Squamous Cell, Solid Tumors, Head & Neck Cancer Trial in Boston (Palbociclib, Gedatolisib)

      Recruiting
      • Lung Cancer Squamous Cell
      • +3 more
      • Boston, Massachusetts
      • +2 more
      Jan 9, 2023

      Mantle Cell Lymphoma Trial (parsaclisib, rituximab, bendamustine)

      Withdrawn
      • Mantle Cell Lymphoma
      • (no location specified)
      Apr 22, 2022